SomaKit TOC
What SomaKit TOC is used for
This medicinal product is for diagnostic use only. After radiolabelling with gallium (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours (GEP-NET) for localizing primary tumours and their metastases.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- SomaKit TOC
- Active substance
- edotreotide
- Disease area
- Neuroendocrine Tumors; Radionuclide Imaging
- Medicine group
- Diagnostic radiopharmaceuticals
- ATC code
- V09IX
- Marketing authorisation holder
- Novartis Europharm Limited
- Authorised in the EU since
- 2016
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is SomaKit TOC used for?
This medicinal product is for diagnostic use only. After radiolabelling with gallium (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours (GEP-NET) for localizing primary tumours and their metastases.
What is the active substance in SomaKit TOC?
SomaKit TOC contains edotreotide.
Who makes SomaKit TOC?
The EU marketing authorisation holder is Novartis Europharm Limited.
Is SomaKit TOC an orphan medicine?
Yes. SomaKit TOC is designated an orphan medicine in the EU, for a rare disease (Neuroendocrine Tumors; Radionuclide Imaging).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU